Abstract： Objective To explore the clinical effect of metformin and gliclazide in the treatment of type 2 diabetes patients.Methods 60 patients with type 2 diabetes from January 2020 to March 2022 were randomly divided into two groups according to the throwing method,30 patients in each group.The control group took gliclazide alone,and the observation group took metformin on the basis of the control group.By observing and comparing the blood glucose level,blood lipid level,hemorheology indicators before and after treatment,and the incidence of hypoglycemia in the two groups at different times.Results Before treatment,there was no significant difference between the two groups in blood glucose levels,blood lipid indicators,and hemorheological indicators(P＞0.05);after treatment,the glucose test fasting blood sugar,blood glucose 1 h after meal,blood glucose 2 h after meal,and glycated hemoglobinin the two groups were lower than before treatment,and the difference was statistically significant(P＜0.05);after treatment,the observation group showed a more significant improvement in blood lipid indicators,with a statistically significant difference(P＜0.05);after treatment,the hemorheological indicators of the two groups were lower than before treatment,and the observation group had a lower level,with a statistically significant difference(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of metformin and gliclazide in the treatment of type 2 diabetes can improve blood sugar and blood lipid,reduce hemorheological indexes,and is safe.